Table 2.

Health-related quality of life (SF-36 domains) in the vitamin D group and the placebo group (n = 187).

	Δ Vitamin D group (n = 94)	Δ Placebo group (n = 93)	β*	B*	95% CI	P
Physical functioning	−0.55 ± 12.77	1.21 ± 11.70	−0.062	−1.51	−4.99; 1.96	0.39
Role limitations physical	−5.32 ± 32.77	4.84 ± 32.61	−0.138	−8.9	−17.16; −0.65	0.04†
Bodily pain	−0.24 ± 19.33	2.40 ± 16.59	−0.07	−2.52	−7.30; 2.27	0.3
General health perceptions	0.37 ± 13.39	3.10 ± 13.61	−0.063	−1.71	−5.44; 2.02	0.37
Mental health	−1.68 ± 11.78	−0.12 ± 13.09	−0.033	−0.83	−4.42; 2.77	0.65
Role limitations emotional	−3.72 ± 34.92	1.08 ± 33.50	−0.063	−4.31	−13.00; 4.37	0.31
Vitality	−2.71 ± 13.35	−1.00 ± 12.17	−0.064	−1.62	−5.11; 1.88	0.36
Social functioning‡	0.00 (−12.50 to 0.00)	0.00 (−12.50 to 0.00)	0.95	0.95	0.80; 1.11	0.49
Physical component summary	−1.50 ± 13.82	2.89 ± 11.39	−0.15	−3.77	−7.26; −0.28	0.04†
Mental component summary‡	0.79 (−6.38 to 6.00)	0.00 (−4.50 to 7.50)	0.93	0.97	0.91; 1.04	0.34

A positive β value indicates an increase in the SF-36 domain in the vitamin D group compared to the placebo group.

^*Adjusted for age, gender, BMI, baseline SF-36 domain, baseline 25-hydroxyvitamin and season of blood collection; ^†P < 0.05; ^‡Using log-transformed values; β of 0.95 (social functioning) indicating a 5% lower SF-36 score in the vitamin D group vs the placebo group after six months.